Carbohydrate-Mediated Tumor Targeting

Sidney Hecht (Inventor)

Research output: Patent

Abstract

The bleomycins (BLMs) are well-known antineoplastic agents. They are particularly useful in the treatment of squamous cell carcinomas and malignant lymphomas. The therapeutic effect of bleomycin analogues is believed to result from their selective oxidative cleavage of DNA and possibly RNA. Much of the site-specific cleavage is thought to be effected by the N-terminal metal-binding domain, the C-terminal bithiazole region, and the linker domain. The least understood structural domain of BLM is the disaccharide moiety. Researchers at the Biodesign Institute of Arizona State University have discovered that the carbohydrate moiety of BLM, by itself, is sufficient for tumor cell targeting. Numerous highly specific analogues of this region have been produced and tested for tumor imaging and the development of novel, targeted chemotherapeutics. Potential Applications Reagents for tumor imaging Novel cancer chemotherapeutics Benefits and Advantages Tumor cells can be specifically imaged and targeted for chemotherapeutic destruction Dowload Original PDF For more information about the inventor(s) and their research, please see Dr. Hecht's departmental webpage
Original languageEnglish (US)
StatePublished - May 29 2009

Fingerprint

Bleomycin
Carbohydrates
Neoplasms
Inventors
DNA Cleavage
Disaccharides
Therapeutic Uses
Antineoplastic Agents
Squamous Cell Carcinoma
Lymphoma
Metals
Research Personnel
RNA
Research
Therapeutics

Cite this

@misc{e07bdabd508e48aea9c13e32d01a0200,
title = "Carbohydrate-Mediated Tumor Targeting",
abstract = "The bleomycins (BLMs) are well-known antineoplastic agents. They are particularly useful in the treatment of squamous cell carcinomas and malignant lymphomas. The therapeutic effect of bleomycin analogues is believed to result from their selective oxidative cleavage of DNA and possibly RNA. Much of the site-specific cleavage is thought to be effected by the N-terminal metal-binding domain, the C-terminal bithiazole region, and the linker domain. The least understood structural domain of BLM is the disaccharide moiety. Researchers at the Biodesign Institute of Arizona State University have discovered that the carbohydrate moiety of BLM, by itself, is sufficient for tumor cell targeting. Numerous highly specific analogues of this region have been produced and tested for tumor imaging and the development of novel, targeted chemotherapeutics. Potential Applications Reagents for tumor imaging Novel cancer chemotherapeutics Benefits and Advantages Tumor cells can be specifically imaged and targeted for chemotherapeutic destruction Dowload Original PDF For more information about the inventor(s) and their research, please see Dr. Hecht's departmental webpage",
author = "Sidney Hecht",
year = "2009",
month = "5",
day = "29",
language = "English (US)",
type = "Patent",

}

TY - PAT

T1 - Carbohydrate-Mediated Tumor Targeting

AU - Hecht, Sidney

PY - 2009/5/29

Y1 - 2009/5/29

N2 - The bleomycins (BLMs) are well-known antineoplastic agents. They are particularly useful in the treatment of squamous cell carcinomas and malignant lymphomas. The therapeutic effect of bleomycin analogues is believed to result from their selective oxidative cleavage of DNA and possibly RNA. Much of the site-specific cleavage is thought to be effected by the N-terminal metal-binding domain, the C-terminal bithiazole region, and the linker domain. The least understood structural domain of BLM is the disaccharide moiety. Researchers at the Biodesign Institute of Arizona State University have discovered that the carbohydrate moiety of BLM, by itself, is sufficient for tumor cell targeting. Numerous highly specific analogues of this region have been produced and tested for tumor imaging and the development of novel, targeted chemotherapeutics. Potential Applications Reagents for tumor imaging Novel cancer chemotherapeutics Benefits and Advantages Tumor cells can be specifically imaged and targeted for chemotherapeutic destruction Dowload Original PDF For more information about the inventor(s) and their research, please see Dr. Hecht's departmental webpage

AB - The bleomycins (BLMs) are well-known antineoplastic agents. They are particularly useful in the treatment of squamous cell carcinomas and malignant lymphomas. The therapeutic effect of bleomycin analogues is believed to result from their selective oxidative cleavage of DNA and possibly RNA. Much of the site-specific cleavage is thought to be effected by the N-terminal metal-binding domain, the C-terminal bithiazole region, and the linker domain. The least understood structural domain of BLM is the disaccharide moiety. Researchers at the Biodesign Institute of Arizona State University have discovered that the carbohydrate moiety of BLM, by itself, is sufficient for tumor cell targeting. Numerous highly specific analogues of this region have been produced and tested for tumor imaging and the development of novel, targeted chemotherapeutics. Potential Applications Reagents for tumor imaging Novel cancer chemotherapeutics Benefits and Advantages Tumor cells can be specifically imaged and targeted for chemotherapeutic destruction Dowload Original PDF For more information about the inventor(s) and their research, please see Dr. Hecht's departmental webpage

M3 - Patent

ER -